Daniel C. Martin - Feb 15, 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
Chief Commercial Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Stock symbol
DCPH
Transactions as of
Feb 15, 2023
Transactions value $
-$17,500
Form type
4
Date filed
2/17/2023, 03:12 PM
Previous filing
Jan 19, 2023
Next filing
Jun 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Award $0 +11.2K +23.04% $0.00 59.5K Feb 15, 2023 Direct F1
transaction DCPH Common Stock Sale -$17.5K -1.16K -1.95% $15.10 58.4K Feb 16, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $0 +44.6K $0.00 44.6K Feb 15, 2023 Common Stock 44.6K $15.48 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was awarded 11,151 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2024, February 15, 2025 and February 15, 2026.
F2 This sale was to cover tax liabilities in the vesting of restricted stock.
F3 This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2023.